Breaking Q2 Financial Results: Gentherm and Esperion Beat Expectations
- August 01st, 2023
- 172 views
Gentherm Incorporated (Nasdaq: THRM) reported strong second quarter 2023 adjusted earnings per share (EPS) of $0.58, surpassing the consensus estimate of $0.52, and revenues of $372.30 million, beating the analysts' expectation of $368.63 million.
The company reaffirmed its full-year 2023 guidance, expecting product revenues between $1.45 billion and $1.55 billion, against a consensus estimate of $1.51 billion for the period.
In pre-market, $THRM was trading at $60.38, reflecting a gain of $0.61 (+1.02%).
In other news, Esperion Therapeutics, Inc. (Nasdaq: ESPR) delivered better-than-expected financial results.
The company reported a Q2 2023 loss of $0.46 per share, outperforming the consensus estimate of a loss of $0.61 per share, and revenues of $25.79 million, surpassing the analysts' forecast of $24.64 million for the period.
In pre-market trading, $ESPR was at $1.70, showing a gain of $0.13 (+8.28%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login